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Mutations in DJ-1, a protein of unknown function,
were recently identified as the cause for an autosomal
recessive, early onset form of familial Parkinson’s dis-
ease. Here we report that DJ-1 is a dimeric protein that
exhibits protease activity but no chaperone activity.
The protease activity was abolished by mutation of Cys-
106 to Ala, suggesting that DJ-1 functions as a cysteine
protease. Our studies revealed that the Parkinson’s dis-
ease-linked L166P mutation impaired the intrinsic fold-
ing propensity of DJ-1 protein, resulting in a spontane-
ously unfolded structure that was incapable of forming
a homodimer with itself or a heterodimer with wild-type
DJ-1. Correlating with the disruption of DJ-1 structure,
the L166P mutation abolished the catalytic function of
DJ-1. Furthermore, as a result of protein misfolding, the
L166P mutant DJ-1 was selectively polyubiquitinated
and rapidly degraded by the proteasome. Together these
findings provide insights into the molecular mechanism
by which loss-of-function mutations in DJ-1 lead to Par-
kinson’s disease.
Parkinson’s disease (PD)1 is an age-related neurodegenera-
tive movement disorder characterized by the degeneration of
dopaminergic neurons in the substantia nigra and the presence
of intraneuronal inclusions known as Lewy bodies (1, 2). Al-
though PD has been known for nearly 2 centuries, the molec-
ular mechanisms underlying the pathogenesis of PD is not
understood, and currently there is no treatment to stop the
progression of this devastating disease. Recent evidence indi-
cates that at least 10 distinct genetic loci, PARK1–PARK10, are
linked to familial forms of PD (3, 4). The responsible genes for
three of these loci, PARK1, PARK2, and PARK5, were found to
encode -synuclein (5), parkin (6), and ubiquitin carboxyl-ter-
minal hydrolase L1 (7), respectively. Studies of these familial
PD gene products have generated valuable insights into PD
pathogenesis and led to the hypothesis that dysfunction in the
ubiquitin-proteasome pathway may be a common mechanism
leading to neurodegeneration in PD (8, 9).
Recently it was reported that mutations in DJ-1 underlie the
PARK7 loci for an autosomal recessive, early onset form of
familial PD (10). To date, three PD-linked DJ-1 mutations have
been identified: a homozygous 14-kb deletion (10) and a com-
pound heterozygous mutation (11), both of which result in the
loss of DJ-1 protein, and a homozygous missense mutation
(L166P) that replaces Leu-166 with a proline in the DJ-1 pro-
tein (10). The complete cosegregation of these mutations with
the PD allele suggests that loss of the normal function of DJ-1
causes this recessively transmitted PD (10).
DJ-1 is a ubiquitously expressed protein initially identified
as an oncogene with transforming activity (12). A connection to
cancer is also suggested by the identification of DJ-1 as a
circulating tumor antigen in breast cancer (13). Human DJ-1
was independently described as RS, a regulatory subunit of a
400-kDa RNA-binding protein complex (14). Rat DJ-1, also
known as CAP-1 (15) and SP22 (16), has been linked to male
infertility induced by exposure to sperm toxicants (17, 18). DJ-1
appears to regulate androgen receptor-mediated gene tran-
scription via its interaction with PIASx (protein inhibitor of
activated STAT) and DJ-1-binding protein (19, 20). In addition,
DJ-1 has been proposed to participate in the cellular defense
against oxidative stress since it undergoes a pI shift from 6.2 to
5.8 upon treatment of cells with H2O2 or paraquat (21, 22).
Despite these observations implicating DJ-1 in multiple cellu-
lar processes, the precise biochemical function of DJ-1 remains
unknown.
DJ-1 is an evolutionarily conserved, 189-amino acid protein
that exhibits significant sequence homology with the PfpI fam-
ily of intracellular proteases (23) and with the ThiJ family of
bacterial proteins involved in thiamin synthesis (24). We and
other groups have recently solved the crystal structure of hu-
man DJ-1, which shows that DJ-1 adopts a helix-strand-helix
sandwich structure similar to the bacterial protease PH1704
and Escherichia coli chaperone protein Hsp31 (25–29). How-
ever, it is unclear whether DJ-1 has a protease or chaperone
function because the Cys-His-(Glu/Asp) catalytic triad and the
quaternary structure of PH1704 and Hsp31 are not conserved
in DJ-1. Furthermore the structural and functional conse-
quences of the PD-associated L166P mutation remain to be
defined. In the present study, we undertook the characteriza-
tion of the molecular and biochemical properties of DJ-1 and
investigated how the structure and function of DJ-1 are altered
by the disease-linked L166P mutation.
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EXPERIMENTAL PROCEDURES
DJ-1 Expression Constructs—The DJ-1 cDNA corresponding to the
entire coding region of human DJ-1 (12) was obtained by PCR. The
L166P and C106A single and double mutant cDNAs were obtained by
site-directed mutagenesis using a PCR overlap extension method (30).
These cDNAs were analyzed on both strands by DNA sequencing to
ensure there were no unwanted changes in the codons. The wild-type
and mutant DJ-1 cDNAs were then used to make the following expres-
sion vectors: pCHA-DJ-1, pMyc-DJ-1, pGFP-DJ-1, and the correspond-
ing L166P and C106A mutant forms, which allow the expression of
amino-terminally HA-, Myc-, or GFP-tagged wild-type and mutant DJ-1
proteins in mammalian cells. All expression constructs were sequenced
to confirm that the fusion was in the correct reading frame.
Antibodies—Two distinct rabbit polyclonal anti-DJ-1 antibodies, P7F
and P7C, were generated against purified full-length recombinant hu-
man DJ-1 protein and a synthetic human DJ-1 carboxyl-terminal pep-
tide ALNGKEVAAQVKAPLVLKD, respectively, using the same proce-
dures as described previously (31). Other antibodies used in this study
include the following: anti-HA (3F10, Roche Applied Science; HA.11,
Covance), anti-Myc (9E10.3, Neomarkers), anti-actin (C4, Chemicon);
and secondary antibodies coupled to horseradish peroxidase (Jackson
ImmunoResearch Laboratories, Inc.).
Immunohistochemistry—Rats were perfused transcardially with 3%
paraformaldehyde, and brain sections were cut at 50-m thickness and
stored in cryoprotectant until use. Sections were rinsed in phosphate
buffer and pretreated for 1 h in a solution containing 8% goat serum, 10
g/ml avidin, 0.1% Triton X-100, 0.9% NaCl, and 50 mM Tris-HCl (pH
7.2). Sections were then incubated for 48 h with rabbit polyclonal
anti-DJ1 antibody P7F or P7C at 1:2000 followed by incubation with
biotinylated goat anti-rabbit secondary antibody (1:200, Vector Labora-
tories). Immunoreactivity was visualized using the standard avidin-
biotinylated peroxidase complex method (Vectastain Elite ABC kit,
Vector Laboratories). For controls, sections were processed in parallel
with primary antibody omitted or with excess amount of immunogens.
Protein Expression and Purification—Wild-type and mutant DJ-1
were expressed in BL21 E. coli cells as untagged proteins (25, 32) and
purified by ammonium sulfate fractionation, Sepharose Q XL ion ex-
change chromatography, and Sephacryl S-100 gel filtration chromatog-
raphy. Fractions containing DJ-1 were identified with SDS-PAGE and
pooled for further studies. Protein concentration was determined by
using the bicinchoninic acid (BCA) assay (Pierce).
Size Exclusion Chromatography—Purified wild-type or L166P mu-
tant DJ-1 protein (1 ml at 10 mg/ml) was loaded on a HiPrep 16/60
Sephacryl S-100 high-resolution column and fractionated by size exclu-
sion chromatography using an KTAprime chromatography system
(Amersham Biosciences). The column was eluted at 4 °C using a flow
rate of 0.5 ml/min in a buffer containing 100 mM NaCl, 1 mM EDTA, 1
mM -mercaptoethanol, and 20 mM Tris-HCl (pH 7.5), and 5-ml frac-
tions were collected. The column was calibrated under identical run-
ning conditions with protein standards (Sigma), including blue dextran
(2000 kDa), -amylase (200 kDa), albumin (66 kDa), carbonic anhy-
drase (29 kDa), cytochrome c (12.4 kDa), and aprotinin (6.5 kDa).
CD Spectroscopy—Far UV CD spectra were obtained using an AVIV
model 62DS CD spectrometer and a quartz cuvette with a path length
of 0.1 or 1 cm. Spectra were recorded at 25 °C from 250 to 200 nm with
a step size of 0.5 nm and a bandwidth of 1.5 nm, and an average of 10
scans was obtained. CD measurements were performed with purified,
untagged wild-type or mutant DJ-1 proteins at a final concentration of
2–35 M in a buffer containing 20 mM Tris-HCl (pH 7.4) and 100 mM
NaCl. Mean residue ellipticity is defined as the observed ellipticity
normalized by the molar concentration of amino acid residues in the
indicated protein. Thermal denaturation was studied by measuring far
UV CD in 1-cm cuvette at 222 nm while the temperature was increased
from 5 °C to 90 °C with a step size of 2 °C. Melting temperature (Tm) is
defined as the temperature at which 50% of the -helical structure
(measured by ellipticity at 222 nm) is denatured. Reversibility of ther-
mal denaturation was assessed in the same cuvette at 222 nm while the
temperature was cooled from 90 °C to 5 °C with a step decrease of 2 °C.
Chaperone Activity Assay—The potential chaperone function of DJ-1
was investigated by using a well established chaperone assay that
measures the ability of a molecular chaperone to suppress the thermal
aggregation of citrate synthase (33). To induce aggregation, 45 M
porcine heart citrate synthase (Sigma) was diluted 1:300 in 40 mM
HEPES-KOH, pH 7.5 at 43 °C in the presence and absence of wild-type
or mutant DJ-1. To monitor the kinetics of thermal aggregation, light
scattering was measured in a PerkinElmer Life Sciences LS55 lumi-
nescence spectrometer in a stirred and thermostatted quartz cell. Both
the excitation and emission wavelengths were set to 500 nm with a slit
width of 2.5 nm. Recombinant murine heat shock protein Hsp25
(Stressgen) was used as a positive control for the chaperone assay.
Protease Activity Assays—Protease activity of DJ-1 and its mutants
was measured by an in-gel protease assay and a continuous fluores-
cence-based protease assay. The in-gel protease assay was carried out
as described previously for determining the protease activity of the PfpI
family of proteases (34, 35). Purified wild-type or mutant DJ-1 protein
(1–100 g) was electrophoresed onto 12% SDS-polyacrylamide gels
containing 0.1% co-polymerized gelatin under non-reducing conditions.
After electrophoresis, the gels were washed in 2.7% Triton X-100 and
then incubated overnight at 37 °C in 200 mM NaCl, 5 mM CaCl2, and 50
mM Tris-HCl (pH 7.4). The gels were stained with Coomassie Brilliant
Blue to visualize zones of gelatin hydrolysis. The fluorescence-based
protease assays were performed as described previously (36) by using
the EnzCheck protease assay kit (Molecular Probes). Purified wild-type
or mutant DJ-1 (1–50 M) was incubated with BODIPY FL-labeled
casein (10 g/ml) in 50 mM Tris-HCl, pH 7.4, 200 mM NaCl, and 5 mM
CaCl2 at 37 °C. An increase in fluorescence upon protease-catalyzed
hydrolysis of BODIPY FL-casein was monitored continuously in a
PerkinElmer Life Sciences LS55 luminescence spectrometer using an
excitation wavelength of 505 nm and emission wavelength of 513 nm.
Kinetic parameters (Km and kcat) were obtained as described previously
(37) by fitting the data to the following equation: v  kcat [S]0/(1 
Km[E]
1). Trypsin (Athena Environmental Sciences, Inc.) was used as a
positive control for both in-gel and fluorescence-based protease assays.
Cell Transfections and Immunoprecipitations—HeLa or SH-SY5Y
cells were transfected with the indicated plasmids using Lipo-
fectAMINE (Invitrogen) as described by the manufacturer. Stable
transfectants were isolated in selection medium containing 0.5 mg/ml
G418 (Invitrogen), and 300 colonies were pooled for further studies.
Cell lysates were prepared from transfected cells and subjected to
immunoprecipitation as described previously (38) using anti-HA anti-
body (3F10). The immunocomplexes were recovered by incubation with
protein G-Sepharose beads (Sigma). After extensive washes, the immu-
nocomplexes were dissociated by boiling in the Laemmli sample buffer
and analyzed by SDS-PAGE and immunoblotting with appropri-
ate primary and secondary antibodies. Antibody binding was visual-
ized by using the enhanced chemiluminescence system (Amersham
Biosciences).
Proteolysis Inhibitor Treatment of Cells—HeLa or SH-SY5Y cells
expressing wild-type or L166P mutant DJ-1 were incubated for 8 h at
37 °C with the proteasome inhibitor MG132 (20 M, Calbiochem), the
lysosomal protease inhibitor chloroquine (100 M, Sigma), or vehicle
(dimethyl sulfoxide (Me2SO); final concentration, 0.1%). Cells were then
lysed, and an equal amount of proteins from each lysate was analyzed
by immunoblotting for HA-tagged DJ-1 and actin. The relative level of
wild-type or mutant DJ-1 was quantified by using the NIH Image
program and normalized against the level of actin. Statistical analyses
were performed by the unpaired Student’s t test.
Ubiquitination Assays—In vivo ubiquitination assays were per-
formed as described previously (39, 40). Briefly HeLa cells were trans-
fected with pcDNA3-myc-ubiquitin in combination with pCHA-DJ-1 or
pCHA-L166P. Twenty-four hours after transfection, the cells were in-
cubated for 8 h with vehicle control (0.1% Me2SO) or proteasome inhib-
itor MG132 (20 M in Me2SO). The cells were then lysed, and an equal
amount of proteins from each lysate was subjected to immunoprecipi-
tation using anti-HA antibodies. Immunoprecipitates were analyzed by
SDS-PAGE followed by immunoblotting with an anti-Myc antibody to
detect Myc-ubiquitin conjugated to wild-type or L166P mutant DJ-1.
[35S]Methionine Pulse-Chase Experiments—Pulse-chase experiments
were performed as described previously (39, 40). SH-SY5Y cells stably
transfected with pCHA-DJ-1 or pCHA-L166P were labeled by incuba-
tion for 1 h with Met/Cys-free Dulbecco’s modified Eagle’s medium
containing 100 Ci of [35S]Met/Cys (1000 Ci/mmol) express protein
labeling mixture (PerkinElmer Life Sciences). After extensive washes,
cells were incubated for the indicated chase time in non-radioactive
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bo-
vine serum and 5 times the normal concentration of methionine and
cysteine. Cells were then lysed, and an equal amount of proteins from
each lysate was immunoprecipitated using an anti-HA antibody.
Immunoprecipitates were resolved by SDS-PAGE and analyzed by a
PhosphorImager (Amersham Biosciences).
RESULTS
Generation of Anti-DJ-1 Antibodies and Characterization of
DJ-1 Protein Expression—The expression and localization of
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DJ-1 protein are poorly characterized, and virtually nothing is
presently known about the distribution of DJ-1 protein in the
nervous system. For characterization of DJ-1 at the protein
level, we generated two distinct rabbit polyclonal anti-DJ-1
antibodies, P7F and P7C, against purified full-length recombi-
nant protein and a carboxyl-terminal peptide of human DJ-1,
respectively. Western blot analysis demonstrated that both
anti-DJ-1 antibodies, but not their corresponding preimmune
controls, recognized the 20-kDa endogenous DJ-1 protein as
well as recombinant DJ-1 protein expressed in bacteria and
mammalian cells (Fig. 1A and data not shown). Preabsorption
of the P7F and P7C antibodies with purified recombinant DJ-1
protein completely eliminated their immunoreactivity to the
recombinant as well as endogenous DJ-1 protein (data not
shown), confirming the specificity of these antibodies. The
lower molecular weight bands in the recombinant DJ-1 lanes
are likely to be the proteolytic products of DJ-1 because they
varied from blot to blot, and none of these bands were detected
when the blots were analyzed with anti-DJ-1 antibodies preab-
sorbed with DJ-1 immunogens.
Using these anti-DJ-1 antibodies, we demonstrated that
DJ-1 is ubiquitously expressed in all tissues tested with high
expression levels in brain, testis, and kidney (Fig. 1B). To
further characterize the expression of DJ-1 in brain, various
brain regions were dissected from adult rats and subjected to
Western blot analysis using the anti-DJ-1 antibodies. For com-
parison, we also analyzed the same samples with antibodies
against parkin and -synuclein. The result shows that these
three PD-associated proteins are widely expressed throughout
the brain with distinct distribution patterns (Fig. 1C). DJ-1
exhibits relatively higher protein expression levels in brain
regions that are affected in Parkinson’s disease, such as the
substantia nigra or ventral midbrain area, compared with the
levels in the hippocampus and cerebral cortical regions.
Immunolocalization of DJ-1 Protein in Rat Brain—We then
used these anti-DJ-1 antibodies to determine the cellular dis-
tribution of DJ-1 protein in rat brain by immunohistochemis-
try. Consistent with the results of Western blot analysis (Fig.
1C), intense DJ-1 immunostaining was observed in the sub-
stantia nigra (Fig. 2E). Nearly all neurons, including dopam-
inergic neurons, in the pars compacta and pars reticulata of the
substantia nigra contained DJ-1 immunoreactivity in their nu-
clei, perikarya, and processes. In the striatum, large interneu-
rons were intensely stained for DJ-1, whereas the medium
spiny neurons were moderately well stained (Fig. 2D).
In addition to the nigral-striatal system, DJ-1 immunoreac-
tivity was widely distributed in many neurons throughout the
brain. In the cerebral cortex, layer V pyramidal cells were
FIG. 1. Expression and distribution of DJ-1 protein. A, specificity of two novel polyclonal anti-DJ-1 antibodies, P7C and P7F. Upper panel,
Western blot analysis of rat brain homogenate and untagged, recombinant (Recomb.) DJ-1 protein expressed in E. coli cells using anti-DJ-1
antibody P7C or P7F. Lower panel, cell lysates prepared from HeLa cells transfected with pCHA-DJ-1 or pCHA vector control were immunopre-
cipitated with anti-HA antibody followed by immunoblotting with anti-DJ-1 antibody P7C. IB, immunoblot; IP, immunoprecipitation. B, tissue
distribution of DJ-1 protein expression. Equal amounts of homogenates (60 g of protein/lane) from the indicated rat tissues were analyzed by
immunoblotting using anti-DJ-1 antibody P7C. Sk., skeletal. C, regional distribution of DJ-1 protein in rat brain compared with parkin and
-synuclein. Equal amounts of homogenates (50 g of protein/lane) from the indicated brain tissues were immunoblotted for DJ-1, parkin,
-synuclein, and actin. Sup., superior; Inf., inferior. All data are representative of at least three independent experiments.
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prominently stained in addition to moderately stained neurons
in all lamina and in all cortical regions (Fig. 2, A and B).
Intense DJ-1 immunostaining was present in the islands of
Calleja, the diagonal band of Broca, piriform cortex, and sep-
tum. In the hippocampus, immunoreactivity was much greater
in interneurons than in dentate gyrus granule cells (Fig. 2F).
Neuronal labeling was also prominent in the entopeduncular
and subthalamic nuclei, globus pallidus, and the basolateral
and central amygdaloid nuclei (Fig. 2C); throughout the thal-
amus (Fig. 2C); in the ventromedial hypothalamic nucleus (Fig.
2G); and in magnocellular neurons of the red nucleus (Fig. 2H).
In the cerebellum, there was strong immunoreactivity in Pur-
kinje cells but not in granule cells (Fig. 2I). In brain stem, the
motor nuclei of the oculomotor, trigeminal, and facial nerves
and the nucleus ambiguus were intensely stained.
Within labeled neurons, DJ-1 immunostaining was localized
in both nucleus and cytoplasm, including neuronal processes
and neuropil. Prominent immunoreactive axons and dendrites
were often seen extending over distances greater than 1 mm
from the soma. In addition to neurons, DJ-1 immunostaining
was also present in oligodendroglia, astrocytes, and cells of the
pia mater, ventricular ependyma, and vascular endothelium,
although these non-neuronal cells were weakly labeled. Similar
staining patterns were obtained with two different anti-DJ-1
antibodies, P7F and P7C, indicating that the observed DJ-1
immunostaining is specific. The specificity of DJ-1 immunore-
activity was further confirmed by preabsorption experiments
and in controls where anti-DJ-1 primary antibody was omitted
(data not shown).
L166P Mutation Causes DJ-1 Protein to Unfold into a “Ran-
dom Coil” Structure—To investigate structural consequences of
PD-linked L166P mutation, we used circular dichroism spec-
troscopy to study the secondary structure of DJ-1 and its mu-
tant proteins (Fig. 3A). At physiological pH, wild-type DJ-1
protein showed a CD spectrum with maximal negative elliptic-
ity at 208 and 222 nm, indicating a substantial amount of
-helical content in the solution structure of DJ-1. Since the
crystal structure of DJ-1 suggests that the highly conserved
cysteine residue at position 106 may play a key role in DJ-1
catalytic function (25–28), we made the C106A mutant DJ-1 by
replacing the Cys-106 residue with an alanine. The CD spec-
trum of the C106A mutant was virtually indistinguishable
from that of wild-type DJ-1, indicating that the C106A muta-
tion has no effect on the DJ-1 structure. In contrast, the L166P
mutant DJ-1 protein exhibited a very different CD spectrum,
showing large negative ellipticity at 200 nm and small neg-
ative values in the 210–230-nm region. This CD spectrum
indicates that the L166P mutant contains high content of ran-
dom coil or unfolded structure and relatively little -helical
structure.
To assess the structural stability of DJ-1 and its mutants, we
performed thermal denaturation experiments by monitoring
ellipticity at 222 nm while the temperature was increased in
steps from 5 °C to 90 °C (Fig. 3B). The results revealed that the
folded structure of DJ-1 was relatively stable and underwent
unfolding with a Tm of 72 °C. The unfolding was reversible as
the CD spectra indicated that the denatured DJ-1 was able to
refold upon stepwise cooling from 90 °C to 5 °C (data not
shown). The C106A mutant behaved similarly to wild-type
DJ-1 in the thermal unfolding and refolding experiments with
a slightly decreased stability (Fig. 3B and data not shown). The
CD spectra of heat-denatured wild-type and C106A mutant
DJ-1 at 90 °C were almost indistinguishable from the spectrum
of the L166P mutant at 25 °C (data not shown), further sup-
porting the notion that the L166P mutant structure (Fig. 3A)
represents an unfolded DJ-1 conformation. Thermal denatur-
ation experiments revealed that the L166P mutant could not be
further unfolded by increasing the temperature to 90 °C (Fig.
3B). The CD spectra of L166P mutant before and after boiling
were virtually identical (data not shown), indicating that the
random coil conformation of the L166P mutant is a stable
structure. Furthermore the thermal refolding experiments
showed that the L166P mutant was unable to fold into a wild-
type DJ-1-like structure by stepwise lowering the temperature
FIG. 2. Immunohistochemical anal-
ysis of DJ-1 protein distribution in
rat brain. A, retrosplenial gyrus. B, layer
V pyramidal neurons in frontal cortex. C,
immunoreactive neurons are present
throughout the thalamus (thal), entope-
duncular nucleus (EP), and central amyg-
daloid nucleus (CeL). Globus pallidus
(GP) is more strongly immunostained
than the caudate-putamen (CPu). D, in
the striatum, large interneurons are gen-
erally more prominently stained than me-
dium spiny neurons. E, substantia nigra
showing pars compacta (middle) and pars
reticulata (lower right corner). F, hip-
pocampal interneurons in the hilus of the
dentate gyrus display DJ-1 immuno-
staining, whereas dentate granule cells
(DG) do not. G, ventromedial nucleus of
the hypothalamus. H, magnocellular neu-
rons in the red nucleus. I, Purkinje cell
layer (PCL) neurons display intense im-
munostaining in contrast to the granular
layer (GL). Scale bar  125 m in A; 30
m in B, D, G, H, and I; 500 m in C; and
60 m in E and F.
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to 5 °C (data not shown). Together these data suggest that the
L166P mutation impairs the intrinsic folding propensity of
DJ-1 protein, resulting in a spontaneously unfolded structure.
L166P Mutant Is Incapable of Forming a Dimeric Structure
in Vitro—Next we performed gel filtration experiments to com-
pare the oligomeric state of wild-type and L166P mutant DJ-1.
As shown in Fig. 4, recombinant DJ-1 protein eluted from the
Sephacryl S-100 gel filtration column as a single peak with an
apparent molecular mass of 38 kDa, which is very close to the
predicted molecular mass of 40 kDa for the dimeric form of
DJ-1. By comparison, no L166P mutant DJ-1 protein was de-
tected in the fractions corresponding to the size of the dimeric
form. Instead a significant portion of L166P mutant protein
was found in the fractions corresponding to the size of the
monomeric form with an apparent molecular mass of 19 kDa
(Fig. 4), indicating that L166P mutant protein exists as a
monomer instead of a dimer in solution. During the course of
protein purification, we noted that the L166P mutant protein
had a higher tendency to undergo aggregation compared with
wild-type DJ-1. Consistent with this notion, a substantial
amount of L166P mutant protein eluted in the void volume
fractions (Fig. 4).
L166P Mutation Prevents the Assembly of the Homodimer
and the DJ-1 L166P Heterodimer in Vivo—We then examined
the in vivo self-association of DJ-1 and its L166P mutant and
the interaction between wild-type and mutant DJ-1 by co-
immunoprecipitation of differentially tagged wild-type and mu-
tant DJ-1 proteins in HeLa cells. As shown in Fig. 5, Myc-
tagged DJ-1 co-immunoprecipitated with HA-tagged DJ-1,
indicating the presence of DJ-1 homodimers in mammalian
cells. In contrast, Myc-tagged L166P mutant was unable to
co-immunoprecipitate with either HA-tagged L166P mutant or
with HA-tagged wild-type DJ-1, indicating that the L166P
mutation not only disrupts the assembly of the homodimer but
also prevents the formation of the heterodimer between wild-
type and L166P mutant DJ-1. Unlike the L166P mutation, the
C106A mutation did not affect the dimerization of DJ-1 (Fig. 5).
By comparison, the C106A/L166P double mutation abolished
the dimer formation, further confirming the inhibitory effect of
L166P mutation on DJ-1 dimerization. Similar results were
also obtained when the co-immunoprecipitation experiments
were carried out with untagged or GFP-tagged wild-type and
mutant DJ-1 proteins (data not shown).
DJ-1 Does Not Appear to Have a Molecular Chaperone Func-
tion—Elucidation of the biochemical function of DJ-1 is crucial
for unraveling the molecular basis of PD pathogenesis. The
significant sequence and structural homology between DJ-1
and E. coli chaperone protein Hsp31 (25, 41) raises an intrigu-
ing possibility that DJ-1 may function as a molecular chaper-
one. To test this possibility, we used a well established chap-
erone assay (33, 41) to determine whether DJ-1 has the ability
to suppress the heat-induced aggregation of the chaperone
substrate citrate synthase. As shown in Fig. 6A, light scatter-
ing measurement revealed that citrate synthase, when incu-
bated at heat shock temperature (43 °C), underwent rapid ag-
gregation with a time course consistent with previous reports
(33, 41). By comparison, no detectable heat-induced aggrega-
tion of DJ-1 or its mutant forms (L166P or C106A) could be
observed when these DJ-1 proteins were incubated alone at
43 °C (Fig. 6A and data not shown). The lack of heat-induced
aggregation of wild-type and mutant DJ-1 is in agreement with
the results (Fig. 3B) of thermal denaturation experiments
measured by CD spectroscopy. As expected, the heat-induced
aggregation of citrate synthase could be effectively suppressed
by an equal molar amount of Hsp25, a known molecular chap-
erone (Fig. 6A). However, under the same experimental condi-
tions, wild-type, L166P mutant, or C106A mutant DJ-1 protein
was unable to inhibit the thermal aggregation of citrate syn-
thase even when provided at 3-fold molar excess (Fig. 6A) or up
to 20-fold molar excess over the substrate protein (data not
shown). Similar negative results were obtained when the ex-
periments were repeated in the presence of 300 M H2O2 (data
not shown), indicating that DJ-1 does not appear to have a
chaperone function in this assay even under the oxidized
conditions.
DJ-1 Functions as a Cysteine Protease—Since DJ-1 also
shares significant sequence and structural homology with the
PfpI family of intracellular proteases (23, 35), we sought to
determine whether DJ-1 possesses intrinsic protease activity.
We first assessed the proteolytic activity of DJ-1 by using the
same in-gel protease assay that was used to demonstrate the
protease activity of PfpI and PH1704 (34, 35). No detectable
proteolytic activity could be observed for DJ-1 protein despite
the robust proteolytic activity exhibited by the positive control
trypsin (data not shown). The failure to detect DJ-1 protease
activity in this assay could be due to the loss of DJ-1 quater-
FIG. 3. Far UV CD spectroscopic analysis of the secondary structure and thermal unfolding of DJ-1 and its mutants. A, CD spectra
of wild-type, L166P mutant, and C106A mutant DJ-1 proteins measured at 25 °C. B, thermal denaturation of DJ-1 and its mutants. Ellipticity was
recorded at 222 nm at temperatures from 5 °C to 90 °C with 2 °C step increases. deg, degrees.
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nary and tertiary structure caused by SDS denaturation during
gel electrophoresis.
We then used a highly sensitive, fluorescence-based protease
assay (36) to investigate the potential protease activity of DJ-1.
This assay allows continuous, real time measurement of pro-
tease activity by using the intramolecularly quenched BODIPY
FL-labeled casein as the substrate. As shown in Fig. 6B, pro-
teolysis of the quenched casein substrate by a protease such as
trypsin releases highly fluorescent BODIPY FL-peptides,
which can be detected as an increase in fluorescence. Incuba-
tion of purified recombinant DJ-1 with the quenched casein
substrate also led to increases in fluorescence with time, indi-
cating that DJ-1 possesses intrinsic proteolytic activity to hy-
drolyze the casein substrate. However, the concentrations of
DJ-1 (e.g. 30 M in Fig. 6B) needed to produce reasonable
fluorescence increases were at least 3 orders of magnitude
higher than the concentrations of trypsin (e.g. 0.1 M in Fig.
6B), indicating that DJ-1 has a weak catalytic activity. Kinetic
studies revealed that DJ-1-mediated casein proteolysis has a
Km value of 133 M and a kcat of 0.0057 s
1, giving a catalytic
efficiency (kcat/Km) of 43 M
1 s1, which is much lower than that
observed for trypsin (250,000 M1 s1). The proteolytic activity
of DJ-1 was not significantly affected by 300 M H2O2 (data not
shown), arguing against the possibility that the DJ-1 protease
function is activated in response to oxidative stress.
Based on the sequence and structural homology of DJ-1 with
the PfpI family of intracellular proteases, it has been proposed
that Cys-106 of DJ-1 may serve as the active site nucleophile
for its catalytic function (25, 26, 28). To examine this possibil-
ity, we assessed the effect of mutation of Cys-106 to an Ala
(C106A) on the protease activity of DJ-1. As shown in Fig. 6B,
the C106A mutation completely abolished the proteolytic activ-
ity of DJ-1. Since the C106A mutation had little effect on the
structure (Fig. 3) or dimerization of DJ-1 (Fig. 5), the lack of the
proteolytic activity of the C106A mutant suggests an essential
role for Cys-106 in the catalytic function of DJ-1. In addition,
we found that the protease activity of DJ-1 is abolished by the
PD-linked L166P mutation (Fig. 6B), demonstrating that
L166P is a loss-of-function mutation.
L166P Mutant, but Not Wild-type DJ-1, Is Selectively Poly-
ubiquitinated in Vivo—In cells, misfolded proteins are usually
recognized and degraded by the ubiquitin-proteasome proteo-
lytic pathway (42, 43). The ubiquitin-proteasome pathway con-
sists of two major steps: the conjugation of ubiquitin to the
substrate and subsequent degradation of the ubiquitinated
substrate protein by the 26 S proteasome. Although the L166P
mutant was recently suggested to undergo degradation by the
ubiquitin-proteasome pathway (44), it remains to be deter-
mined experimentally whether the L166P mutant is indeed
ubiquitinated. To address this issue, we used a well established
in vivo ubiquitination assay (39, 45) to measure the ubiquiti-
nation of DJ-1 and its L166P mutant in mammalian cells.
Lysates from HeLa cells expressing Myc-tagged ubiquitin in
combination with HA-tagged wild-type or L166P mutant DJ-1
were subjected to immunoprecipitation with anti-HA antibod-
ies followed by immunoblotting with anti-Myc antibodies to
detect ubiquitin-conjugated DJ-1 proteins (Fig. 7). As expected,
treatment of cells with the proteasome inhibitor MG132 re-
sulted in accumulation of ubiquitinated substrate proteins
FIG. 4. Gel filtration analysis of the oligomeric state of DJ-1 and its L166P mutant. A, elution profile of wild-type DJ-1 (left panel) and
L166P mutant DJ-1 (right panel) through a Sephacryl S-100 high-resolution gel filtration column. mAU, milliabsorbance units at 280 nm. B, plot
of the observed elution of DJ-1 and L166P mutant protein against the calibration standard curve reveals that DJ-1 exists as a dimer (38 kDa),
whereas L166P is a monomer (19 kDa) in solution. Standards used for column calibration are blue dextran (2000 kDa), -amylase (200 kDa),
albumin (66 kDa), carbonic anhydrase (29 kDa), cytochrome c (12.4 kDa), and aprotinin (6.5 kDa).
FIG. 5. Homo- and hetero-oligomerization of DJ-1 and its mu-
tants in vivo. Lysates from HeLa cells transfected with the indicated
plasmids encoding HA- or Myc-tagged wild-type DJ-1, L166P single
mutant, C106A single mutant, or C106A/L166P double mutant were
subjected to immunoprecipitation with anti-HA antibody. The HA- and
Myc-tagged wild-type and mutant DJ-1 proteins in the lysates (Input)
and immunoprecipitates were detected by immunoblotting. Control im-
munoblotting for actin confirms the specificity of the co-immunoprecipi-
tations. All data are representative of at least three independent ex-
periments. IP, immunoprecipitation.
Disruption of DJ-1 Structure and Function by L166P Mutation 8511
compared with vehicle-treated controls (Fig. 7, Input lanes).
Immunoprecipitation results showed that only the L166P mu-
tant, but not wild-type DJ-1, is ubiquitinated. The ubiquitina-
tion of the L166P mutant seems to be polyubiquitination be-
cause ubiquitinated L166P mutant proteins were only
accumulated in the MG132-treated cells and appeared as a
high molecular weight smear (Fig. 7).
Misfolded L166P Mutant Protein Is Degraded by the Protea-
some—We then measured the stability and steady-state levels
of wild-type and L166P mutant DJ-1 to determine whether the
polyubiquitination of L166P mutant targets it for degradation
by the 26 S proteasome. First we performed pulse-chase exper-
iments to compare the turnover rate of HA-tagged DJ-1 and its
L166P mutant in stably transfected human neuroblastoma
SH-SY5Y cells. As shown in Fig. 8A, the half-life of wild-type
DJ-1 was 33 h, whereas the half-life of the L166P mutant was
reduced to 1 h, indicating that the L166P mutant protein is
considerably unstable compared with wild-type DJ-1. Consist-
ent with this result, Western blot analysis revealed that the
steady-state expression level of the L166P mutant was signif-
icantly lower compared with wild-type DJ-1 (Fig. 8B). The
steady-state level of the L166P mutant was increased by treat-
ment of cells with the proteasome inhibitor MG132 but not by
treatment with the lysosomal protease inhibitor chloroquine
(Fig. 8B). These results, together with the ubiquitination data
(Fig. 7), provide strong support for a role of the L166P mutation
in provoking the degradation of the mutant protein by the
ubiquitin-proteasome pathway.
DISCUSSION
While monogenic familial forms of Parkinson’s disease are
rare, molecular studies of the underlying gene products respon-
sible for these PD cases can provide novel insights into the
pathogenic mechanisms of this devastating illness. To eluci-
date the role of DJ-1 in normal physiology and in PD patho-
genesis, we generated two novel anti-DJ-1 antibodies and char-
acterized DJ-1 protein expression by Western blot analysis and
immunohistochemistry. Our results indicated that DJ-1 pro-
tein is abundantly expressed in rat brain where it is enriched in
neurons. Consistent with previous studies in non-neuronal
FIG. 6. Functional characterization of the catalytic activity of DJ-1 and its mutants. A, the potential chaperone activity of DJ-1 was
assessed by the ability to suppress the aggregation of citrate synthase at 43 °C. Light scattering measurements of citrate synthase (0.15 M) in the
absence (trace 1) or presence of 0.45 M wild-type human DJ-1 (trace 2), C106A mutant (trace 3), or L166P mutant DJ-1 (trace 4) or 0.15 M murine
Hsp25 (trace 5). B, the protease activity of DJ-1 was assessed by a continuous, real time fluorescence-based protease assay using BODIPY
FL-casein as the substrate. Fluorometric recordings of 0.1 M trypsin (trace 1) and 30 M wild-type human DJ-1 (trace 2), C106A (trace 3), L166P
mutant DJ-1 (trace 4), or bovine serum albumin (trace 5) are shown. AU, arbitrary units.
FIG. 7. L166P mutant DJ-1 protein
is polyubiquitinated in mammalian
cells. HeLa cells were transfected with
the indicated plasmids and incubated in
the absence or presence of proteasome in-
hibitor MG132 for 8 h before harvest. Cell
lysates were subjected to immunoprecipi-
tation with anti-HA antibody followed by
immunoblotting with anti-Myc antibody
to detect Myc-ubiquitin conjugated to
DJ-1 proteins. The blot was then stripped
and reprobed with anti-DJ-1 antibody
P7C. IP, immunoprecipitation; IB, immu-
noblot; Ub, ubiquitin; Ubn, polyubiquitin.
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cells (10, 12, 14), endogenous DJ-1 protein was localized to both
nucleus and cytoplasm of neurons, suggesting that DJ-1 has a
cytoplasmic and a nuclear function. The presence of DJ-1 in
neuronal processes and neuropil suggests that DJ-1 may par-
ticipate in neuronal and/or synaptic function. The abundant
expression of DJ-1 in neurons vulnerable to PD (e.g. substantia
nigra) supports a role for DJ-1 in PD pathogenesis. However,
like other PD gene products such as -synuclein and parkin,
DJ-1 protein was not confined to these vulnerable neurons but
rather was widely distributed throughout the brain. It is im-
portant to find out why loss-of-function mutations in DJ-1
cause selective neurodegeneration in the substantia nigra.
By using gel filtration chromatography and co-immunopre-
cipitation analysis, we showed that DJ-1 exists as a dimer in
solution, which is in agreement with recent reports (26, 27, 44).
Our circular dichroism spectroscopic analyses revealed that,
consistent with the crystal structure, the solution structure of
DJ-1 contains substantial amount of -helical structure. The
CD data indicated that the solution structure of DJ-1 is a stable
structure that unfolds with a melting temperature of 72 °C.
Since the gel filtration profile and the CD spectrum of DJ-1
were unaltered by a 10-fold dilution of the DJ-1 protein con-
centrations used in these analyses (data not shown), it appears
that the DJ-1 dimer does not easily dissociate into monomers.
The lack of a monomer peak in the gel filtration profile of DJ-1
suggests that DJ-1 does not exist in monomer-dimer equilib-
rium in solution.
The crystal structure of DJ-1 reveals a high degree of struc-
tural similarity between DJ-1 and the bacterial protease
PH1704 and E. coli chaperone protein Hsp31 (25–29). How-
ever, unlike PH1704 and Hsp31, DJ-1 does not have a Cys-His-
(Glu/Asp) catalytic triad. Instead DJ-1 contains the putative
nucleophile Cys-106, which has the potential to form a Cys-His
diad. The lack of a complete catalytic triad implies that DJ-1
may not have a protease function, a hypothesis that seemed to
be supported by the failure to detect the protease activity of
DJ-1 in assays using bovine serum albumin or azocasein as the
substrate (27, 29). On the other hand, it has been proposed that
DJ-1 may have a protease function by using the Cys-His diad
as the catalytic mechanism (26). A fully functional Cys-His
catalytic diad has been demonstrated in several cysteine pro-
teases, such as the caspases (46, 47). Interestingly, by using a
fluorescence-based protease assay that is at least 100 times
more sensitive than the bovine serum albumin or azocasein
assay (36), we were able to demonstrate that purified recombi-
nant DJ-1 protein possesses intrinsic protease activity. This
activity was completely abolished by the mutation of Cys-106 to
an Ala, providing strong support for the function of DJ-1 as a
cysteine protease.
Our kinetic studies revealed that the catalytic efficiency
(kcat/Km) of purified DJ-1 protein is very low (43 M
1 s1)
compared with trypsin, but it is comparable to the kcat/Km
values reported for purified herpes simplex virus-1 protease (38
M1 s1) and adenovirus protease (24 M1 s1) (48, 49). The low
catalytic efficiency of DJ-1 could be due to the fact that the
BODIPY FL-casein is a poor substrate for DJ-1, and it is
possible that DJ-1 may exhibit much higher catalytic efficiency
toward its endogenous substrates. In addition, there may be a
cellular cofactor(s) or other activation mechanism(s) for in-
creasing the catalytic efficiency of the DJ-1 protease in vivo.
Identification of such cofactors and endogenous substrates
would be crucial steps toward a mechanistic understanding of
DJ-1 action in normal physiology and in PD pathogenesis.
Because DJ-1 exhibits significant sequence and structural
homology to E. coli chaperone protein Hsp31, we tested
whether purified recombinant DJ-1 protein possesses intrinsic
chaperone activity. Although the positive control Hsp25 exhib-
ited robust chaperone activity in suppressing the heat-induced
FIG. 8. Polyubiquitination of L166P mutant DJ-1 targets it for degradation by the proteasome. A, human neuroblastoma SH-SY5Y
cells expressing HA-tagged wild-type or L166P mutant DJ-1 were pulse-labeled for 1 h with Dulbecco’s modified Eagle’s medium containing
[35S]Met/Cys, chased with non-radioactive Met/Cys for the indicated time, and then lysed. 35S-Labled wild-type or mutant DJ-1 proteins were
immunoprecipitated with anti-HA antibodies and detected by SDS-PAGE and autoradiography. The levels of HA-tagged wild-type or L166P
mutant DJ-1 were quantified using a PhosphorImager and plotted as relative to the corresponding DJ-1 levels at 0 h. Data are shown as mean 
S.E. (error bars) of the results from at least three independent experiments. B, effect of L166P mutation on DJ-1 degradation was blocked by
proteasome inhibitors. SH-SY5Y cells expressing HA-tagged wild-type or L166P mutant DJ-1 were incubated for 8 h at 37 °C with vehicle control
(0.1% Me2SO), 20 M MG132, or 100 M chloroquine. Cell lysates were analyzed by immunoblotting using antibodies against the HA tag or actin.
The relative level of wild-type or mutant DJ-1 was measured by quantification of the intensity of the 20-kDa DJ-1 band and normalized to the actin
level in the corresponding cell lysate. The bar graph shows the results (mean  S.E.) from at least three independent experiments. The asterisk
indicates a statistically significant (p  0.03) increase in the level of L166P mutant DJ-1 in MG132-treated cells versus vehicle-treated controls.
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aggregation of the chaperone substrate citrate synthase, our
chaperone assays failed to detect any chaperone activity for
purified DJ-1. This result is in contrast with a recent report
(29) showing that DJ-1 has chaperone activity in suppressing
the heat-induced aggregation of citrate synthase. The reason
for this discrepancy is unclear. Since we obtained negative
chaperone activity results for different batches of purified DJ-1
and since we showed that the purified DJ-1 retained its intact
conformation and exhibited protease activity, it seems unlikely
that the chaperone activity of DJ-1 is lost during purification.
In this study, we also investigated the structural and func-
tional consequences of PD-linked L166P DJ-1 mutation. In the
crystal structure of wild-type DJ-1, Leu-166 is located in the
middle of helix H7, which, together with helix H8, mediates the
dimerization of DJ-1. Based on this information, it was postu-
lated that mutation of Leu-166 to Pro may act as a helix
breaker to bend helix H7, thus perturbing the packing inter-
actions at the dimer interface, leading to the disruption of the
DJ-1 dimer (10, 25–29). The evidence presented here indicates
that the structural consequence of the L166P mutation is much
more severe than simply disrupting the DJ-1 dimerization or
quaternary structure. Our CD results suggest that the L166P
mutation impairs the intrinsic folding propensity of DJ-1 pro-
tein, resulting in the formation of a spontaneously unfolded
protein with a random coil conformation. The disordered struc-
ture of the L166P mutant protein provides an explanation for
the failure to obtain the crystal of the L166P mutant (25, 26).
Recently it was reported that the L166P mutation signifi-
cantly reduces the signal in yeast two-hybrid interaction as-
says, although it is unclear whether the lack of signal is due to
a reduced capacity for self-association or due to lower expres-
sion levels of the L166P mutant protein in yeast (44). In con-
trast, gel filtration analysis of lysates from L166P mutant-
expressing cells showed that the mutant protein eluted in the
fractions with a higher molecular mass (68 kDa) than a dimer
(40 kDa), suggesting that the mutant forms either a “higher
order” homo-oligomer or a complex with an unidentified protein
(50). To clarify the effect of the L166P mutation on the oligo-
meric state and self-association of DJ-1, we performed gel fil-
tration experiments with purified recombinant proteins and
co-immunoprecipitation studies in transfected cells. Our re-
sults indicated that the L166P mutant protein is monomeric in
solution, incapable of self-associating into a homo-oligomeric
structure. Moreover the L166P mutant protein is incapable of
interacting with wild-type DJ-1 to form a heterodimer. These
results, together with our CD data, suggest that the inability of
the L166P mutant protein to form a homodimer or a het-
erodimer is a direct consequence of impaired DJ-1 protein
folding caused by the PD-linked point mutation. The inability
of the L166P mutant to interact with wild-type DJ-1 is inter-
esting because it predicts that, in human subjects with het-
erozygous L166P mutation, the L166P mutant does not act in a
dominant negative manner to inhibit normal DJ-1 function by
sequestering wild-type DJ-1 protein. This prediction is consist-
ent with the observation that only the homozygous L166P
mutation carrier exhibits Parkinsonian symptoms (10).
Our study demonstrated that the L166P mutation not only
disrupted the structure of DJ-1 but also abolished the protease
function of DJ-1. Moreover the L166P mutant, but not wild-
type DJ-1, was selectively polyubiquitinated and subsequently
degraded by the 26 S proteasome. How the L166P mutant
protein is specifically recognized and earmarked for ubiquitin-
mediated proteolysis is unclear. One possibility is that the
L166P mutation-induced misfolding of DJ-1 protein leads to
exposure of cryptic ubiquitination/degradation signals. The na-
ture of such signals is unknown, but it has been proposed that
exposed hydrophobic domains normally buried in the interior of
the protein or in the protein-protein interaction interfaces may
serve as recognition signals for the ubiquitination machinery
(42, 43, 51). Interestingly recent evidence indicates that the
PD-associated E3 ubiquitin-protein ligase parkin may facili-
tate the ubiquitination and degradation of misfolded proteins
such as Pael-R and the polyglutamine-containing proteins in
conjunction with the molecular chaperone Hsp70 and its bind-
ing partner carboxyl terminus of Hsp70-interacting protein
(52–54). It would be worthwhile to determine whether parkin
has a role in facilitating the ubiquitination of the L166P mu-
tant DJ-1 protein.
The L166P mutation has been proposed to have the simple
effect of promoting DJ-1 degradation, thereby functionally
mimicking the deletion mutation in reducing net DJ-1 protein
within the cell (44, 50). In contrast to this proposal, our results
indicated that the fundamental effect of the L166P mutation is
the disruption of DJ-1 protein folding, resulting in a spontane-
ously unfolded protein that is incapable of carrying out its
catalytic function. Thus, the L166P mutation is a bona fide
loss-of-function mutation. We have presented evidence sup-
porting a function of DJ-1 as a cysteine protease, although DJ-1
may require a cofactor or other activation mechanism to make
it more catalytically efficient. A protease function of DJ-1
would put DJ-1 in a similar pathogenic pathway as other
familial PD gene products (-synuclein, parkin, and ubiquitin
carboxyl-terminal hydrolase L1) and support the hypothesis
that dysfunction in protein degradation is a common cause for
PD. Further investigation of the biochemical function of DJ-1
should lead to a better understanding of the pathogenic mech-
anisms underlying PD.
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